1. Keiser O, Fellay J, Opravil M, et al. Adverse events to antiretrovirals in the Swiss HIV Cohort Study. Antivir Ther. 12(8):1157-64. 2007.
  2. Orkin C, Squire KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovor Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-I Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019; 68(4):535-544.
  3. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 372:646-55, 2008.
  4. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabone, for the initial treatment of HIV infection. AIDS Res Ther. 5:5, 2008.
  5. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naïve, HIV-1- infected patients: 96-week analysis. AIDS. 23:1679-88, 2009.
  6. Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
  7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naïve Patients. JAMA, 292:191-201, 2004.
  8. Moyle GJ, Stellbrink HJ, Compston J, et al. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther. 18:905-13, 2013.
  9. Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018 Jul 18;67(3):411-419.
  10. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 352:48-62, 2005.
  11. O’Halloran J, Sahrmann J, Olsen M, et al. Incident diabetes associated with integrase strand transfer inhibitor initiation. Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 516.
  12. Van Wyk、Ait-Khald M, Santos J, et al. Improved metabolic parameters after switching from TAF-based 3-0r 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): the TANGO study. 23rd International AIDS Conference 2020 Absr OAB0606.
  13. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 349:1993-2003, 2003.
  14. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 18:1811-17, 2004.
  15. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, et al. Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. N Engl J Med. 356:1723-35, 2007.
  16. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 201(3):318-30. 2010
  17. Ryom L,Lundgren JD, El-Sadr WM,et al.Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV. 5(6):e291-e300. 2018
  18. D:A:D Study Group, Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: amulticohort collaboration. Lancet. 371:1417-26, 2008.
  19. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 22:F17-F24, 2008.
  20. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr, 51:20-28, 2009.
  21. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr. 61:441-47, 2012.
  22. D:A:D Study Group, Friis-Møller N, Ryom R, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Cardiol 23: 214-23, 2016.
  23. Isezuo SA, Makusidi MA. Metabolic dysfunctions in non-antiretroviral treated HIV/AIDS patients. Niger J Clin Pract. 12:375- 78, 2009.
  24. Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol. 150:4601-9, 1993.
  25. Gutierrez J, Albuquerque ALA, Falzon L. HIV infection as vascular risk: A systematic review of the literature and meta-analysis. PLoS One.12(5):e0176686. 2017.
  26. Maggi P, Di Biagio A, Rusconi S, et al. Cardiovascular risk and dyslipidemia among persons living with HIV: a review. BMC Infect Dis.17(1):551. 2017.
  27. Aberg JA, Gallant JE, Ghanem KG, et al; Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America. Clin Infect Dis. 58(1):1-10. 2014.
  28. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr. 35:538-9, 2004.
  29. DHHS: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV (Feb. 24, 2021). https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  30. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 49:626-35, 2009.
  31. Hamada Y, Nishijima T, Watanabe K, et al. High Incidence of Renal Stones Among HIV-Infected Patients on Ritonavir-Boosted Atazanavir Than in Those Receiving Other Protease Inhibitor-Containing Antiretroviral Therapy. Clin Infect Dis. 55(9):1262-9, 2012.
  32. Nishijima T, Hamada Y, Watanabe K, et al. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients. PLoS One, 8:e77268, 2013.
  33. Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol, 4:804-11, 2009.
  34. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIVpositive patients. AIDS. 24:1667-78, 2010.
  35. Young J, Schäfer J, Fux CA, et al. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS, 26:567-75, 2012.
  36. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 21:1273-81, 2007.
  37. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIVinfected patients: a retrospective cohort study of Japanese patients. PLoS One. 6:e22661, 2011.
  38. Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS. 23:1971-75, 2009.
  39. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse- transcriptase inhibitor-based therapy. J Infect Dis. 197:102-8, 2008.
  40. Nishijima T, Shimbo T, Komatsu H, et al. Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study. J Infect Chemother, 19:850-7, 2013.
  41. Gatanaga H, Nishijima T, Tsukada K, et al. Clinical importance of hyperbeta-2-microglobulinuria in patients with HIV-1 infection on tenofovir-containing antiretroviral therapy. J Acquir Immune Defic Syndr. 65:e155-7, 2014.
  42. Ruane PJ, DeJesus E, Berger D, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr.63(4):449-55.2013.
  43. Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis.16(1):43-52. 2016.
  44. Raffi F, Orkin C, Clarke A, et al. Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. J Acquir Immune Defic Syndr.75(2):226-31. 2017.
  45. Post FA, Tebas P, Clarke A, et al. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr.74(2):180-4. 2017.
  46. Wohl D, Oka S, Clumeck N, et al. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr.72(1):58-64. 2016.
  47. Arribas JR, Thompson M, Sax PE, et al. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. J Acquir Immune Defic Syndr.75(2):211-218. 2017.
  48. Yanagisawa N, Ando M, Ajisawa A, et al. Clinical Characteristics of Kidney Disease in Japanese HIV-Infected Patients. Nephron Clin Pract. 118:c285-c291, 2011.
  49. 村松 崇, 柳澤如樹, 近澤悠志, 他.本邦のHIV感染者における慢性腎臓病の有病率 2施設での調査結果.感染症学雑誌 87:14-21, 2013
  50. Fernando SK, Finkelstein FO, Moore BA, et al. Prevalence of chronic kidney disease in an urban HIV infected population. Am J Med Sci. 335:89-94, 2008.
  51. Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV-1-infected patients. AIDS. 21:1119-27, 2007.
  52. Nishijima T, Kawasaki Y, Tanaka N, et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1- infected patients with low body weight: results from 10 years of follow-up. AIDS, 28:1903-10, 2014.
  53. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 61(1):32-40, 2012.
  54. Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol, 75:990-6, 2013.
  55. Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. J Infect Dis. 210(3):354-62. 2014.
  56. 宮崎有紀,楠木靖史,小島裕人,他. 日本人を含む世界のHLA-B*57:01分布について─アバカビル過敏症に対する考察 ─日本エイズ学会誌19 : 24-28, 2017.
  57. Honda H, Tsukada K, Yazaki H, et al. Low incidence of abacavir-associated hypersensitivity reactions in Japanese HIV-1- infected patients. 4th IAS Conference 2007, Sydney, MOPEB005
  58. Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 20:2165-74, 2006.
  59. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 22:395-402, 2008.
  60. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acuir Immune Defic Syndr. 51:554-61, 2009.
  61. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 23:1519-29, 2009.
  62. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther. 13:1077-82, 2008.
  63. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 25:387-94, 2009.
  64. Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection. AIDS. 23:1297-1310, 2009.
  65. European AIDS Clinical Society (EACS) Guidelines. Version10.1 – October, 2020. http://www.europeanaidsclinicalsociety.org/よりダウンロード可能
  66. Mollan KR, Smurzynski M, Eron JJ, et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med, 161:1-10, 2014.
  67. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 45:1230-7, 2007.
  68. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice. AIDS. 30(18):2831-4. 2016.
  69. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 18(1):56-63. 2017.
  71. Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis.17(1):622. 2017.
  72. McComsey G. and Lonergan JT. Mitochondrial Dysfunction: Patient Monitoring and Toxicity Management. J Acquir Immune Defic Syndr. 37:S30-S35, 2004.
  73. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 15:717-23, 2001.
  74. A Arenas-Pinto, AD Grant, S Edwards, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect. 79:340-3, 2003.
  75. HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. AIDS. 18:1403-12, 2004.
  76. Schambelan M, Benson CA, Carr A, et al; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 31:257-75, 2002.
  77. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia and insulin resistance. Lancet. 351:1881-3, 1998.
  78. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:871- 5, 1998.
  79. McComsey GA, Ward DJ, Hessenthaler SM, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis. 38: 263-70, 2004.
  80. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 53(2):185-96. 2011.
  81. Sax PE, Erlandson KM, Lake JE et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020; 71(6):1379-1389.
  82. Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019; 381(9):803-815.
  83. Bourgi K, Rebeiro PF, Turner M et al. Greater weight gain in treatment naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis. 2020; 70(7):1267-1274.
  84. Bourgi K, Jenkins C, Rebeiro PF, et al. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. J Int AIDS Soc. 2020 Apr;23(4):e25484.
  85. Bedimo R, Li X, Adam-Huet B, et al. Different BMI changes following PI-and InSTI-based ART initiation by sex and race. Presented at: Conference on Retroviruses and Opportunistic Infections; 2019; Seattle, WA.
  86. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 Oct;7(10):e666-e676.
  87. McComsey GA, Sax P, Althoff KN, et al. Weight gain after switching different integrase strand transfer inhibitors(InSTIs). Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 503.
  88. Gomez M, Seybold U, Roider J, et al. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2019; 47(1): 95-102.
  89. Mallon. 23rd International AIDS Conference 2020 Abstr OAB0604.
  90. Palella F, Hou Q, Li J, et al. Weight gain among PWH who switch to ART-containing InSTIs or TAF. Presented at: virtual Conference on Retroviruses and Opportunistic Infections; 2021 Absr 504.
  91. Hare CB, Coll J, Ruane P, et al. The phase 3 DISCOVER study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Lancet 2020; 396:236-54.
  92. Orkin C, Elion R, Thompson M, et al. Changes in weight and BMI with first-line doravirine-based therapy. AIDS. 2021 Jan 1;35(1):91-99.
  93. Bedimo R, Adams-Huet B, Taylor BS, et al. Integrase inhibitor-based HAART is associated with greater BMI gains in blacks, Hispanics and women. Presented at: IDWeek; 2018; San Fransisco, CA.
  94. HIV感染症治療薬共同使用成績調査 2020報告書、シミックPMS社 https://www.hrd.gr.jp/common/kyoudou/index.html からダウンロード可能.
  95. Hill A, Mac Cann KM, Polkington V, et al. Risk of metabolic syndrome, diabetes, and cardiovascular disease in Advance trial. Presented at: Conference on Retroviruses and Opportunistic Infections; 2020; Boston, abstract 81.
  96. Petoumenos K, Kuwanda L, Ryom L, et al. Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study. J Acquir Immune Defic Syndr. 2020 Dec 17.
  97. Kikuchi Y, Genka I, Ishizaki A. et al. Serious Bradyarrhythmia That Was Possibly Induced by Lopinavir-Ritonavir in 2 Patients with Acquired Immunodeficiency Syndrome. Clin Infect Dis. 35(4), 488-90, 2002.
  98. Zembower TR, Gerzenshtein L, Coleman K, et al. Severe rhabdomyolysis associated with raltegravir use. AIDS. 22(11):1382-4, 2008.
  99. Madeddu G, De Socio GV, Ricci E, et al. Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. Int J Antimicrob Agents. 45(3):289-94, 2015.
  100. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. Complicated atazanavir-associated cholelithiasis: a report of 14cases. Clin Infect Dis. 55(9):1270-2, 2012.
  101. Nishijima T, Shimbo T, Komatsu H, et al. Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. J Antimicrob Chemother. 69(5):1385-9, 2014.
  102. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018.
  103. Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827-840.
  104. Raesima MM, Ogbuabo CM, Thomas V, et al. Dolutegravir use at conception - additional surveillance data from Botswana. N Engl J Med. 2019;381(9):885-887.
  105. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.
  106. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States. (米国DHHS、Feb. 10, 2021). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines